MX2023004554A - Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs. - Google Patents

Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.

Info

Publication number
MX2023004554A
MX2023004554A MX2023004554A MX2023004554A MX2023004554A MX 2023004554 A MX2023004554 A MX 2023004554A MX 2023004554 A MX2023004554 A MX 2023004554A MX 2023004554 A MX2023004554 A MX 2023004554A MX 2023004554 A MX2023004554 A MX 2023004554A
Authority
MX
Mexico
Prior art keywords
psilocybin
benzodiazepines
regimen
following
increase sensitivity
Prior art date
Application number
MX2023004554A
Other languages
English (en)
Inventor
Molly Tabitha Hickey
Original Assignee
Compass Pathfinder Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compass Pathfinder Ltd filed Critical Compass Pathfinder Ltd
Publication of MX2023004554A publication Critical patent/MX2023004554A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción proporciona métodos para tratar a un paciente que lo necesite, que comprenden la administración conjunta al paciente de una dosis terapéuticamente eficaz de psilocibina y una o más benzodiazepinas. La presente descripción también proporciona métodos para reducir el período de descanso con ISRS en pacientes antes de la administración de la terapia con psilocibina.
MX2023004554A 2020-10-21 2021-10-21 Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs. MX2023004554A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063094624P 2020-10-21 2020-10-21
PCT/EP2021/079287 WO2022084480A1 (en) 2020-10-21 2021-10-21 Use of benzodiazepines to increase sensitivity to psilocybin following a chronic ssri regimen

Publications (1)

Publication Number Publication Date
MX2023004554A true MX2023004554A (es) 2023-05-08

Family

ID=78414638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004554A MX2023004554A (es) 2020-10-21 2021-10-21 Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.

Country Status (10)

Country Link
EP (1) EP4232047A1 (es)
JP (1) JP2023546238A (es)
KR (1) KR20230096003A (es)
CN (1) CN116940362A (es)
AU (1) AU2021363627A1 (es)
CA (1) CA3193308A1 (es)
GB (1) GB2615708A (es)
IL (1) IL302258A (es)
MX (1) MX2023004554A (es)
WO (1) WO2022084480A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020358720A1 (en) 2019-10-01 2022-04-21 Empyrean Neuroscience, Inc. Genetic engineering of fungi to modulate tryptamine expression
WO2023130078A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified mycelium for producing psychotropic alkaloids
US12060328B2 (en) 2022-03-04 2024-08-13 Reset Pharmaceuticals, Inc. Co-crystals or salts of psilocybin and methods of treatment therewith
WO2023220367A1 (en) * 2022-05-13 2023-11-16 Reset Pharmaceuticals, Inc. Administration of a psychedelic compound by intramuscular injection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin

Also Published As

Publication number Publication date
CA3193308A1 (en) 2022-04-28
WO2022084480A1 (en) 2022-04-28
EP4232047A1 (en) 2023-08-30
KR20230096003A (ko) 2023-06-29
GB2615708A (en) 2023-08-16
IL302258A (en) 2023-06-01
CN116940362A (zh) 2023-10-24
JP2023546238A (ja) 2023-11-01
GB202307291D0 (en) 2023-06-28
AU2021363627A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
MX2023004554A (es) Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.
MX2021002886A (es) Terapia de combinacion para el tratamiento de cancer de mama triple negativo.
RU2708374C2 (ru) Комбинированная терапия для лечения рака
MX2019010733A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
MX2009007597A (es) Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
Zhu et al. Acupuncture for quality of life in gastric cancer patients undergoing adjuvant chemotherapy
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
MX2021009051A (es) Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
Razzaghdoust et al. Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy
PH12020551726A1 (en) Treatment of atopic dermatitis
CL2018002734A1 (es) Métodos de tratamiento con vitamina d
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
Jordan et al. Trabectedin: Supportive care strategies and safety profile
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
Bali et al. Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2024005632A (es) Tratamiento de la depresion resistente al tratamiento con psilocibina.
MX2022016410A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.
MX2024001892A (es) Una combinacion terapeutica que comprende un antagonista de tigit, un antagonista de pd-1 y uno o varios agentes quimioterapeuticos.
CN105380956A (zh) 一种治疗白血病的含艾德拉尼的药物组合物及应用